Cytosolic phospholipase A2alpha reigns supreme in arthritis and bone resorption.
Bonventre
Jospeh
J
Renal Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. joseph_bonventre@harvard.edu
D000818:Animals; D001169:Arthritis, Experimental / Q000201:enzymology*; D001862:Bone Resorption / Q000201:enzymology*; D015232:Dinoprostone / Q000502:physiology; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D054513:Group IV Phospholipases A2; D007375:Interleukin-1 / Q000494:pharmacology; D020935:MAP Kinase Signaling System / Q000187:drug effects; D051379:Mice; D008811:Mice, Inbred DBA; D018345:Mice, Knockout; D018448:Models, Immunological; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism; D010010:Osteoclasts / Q000166:cytology; D010641:Phenotype; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000172:deficiency / Q000235:genetics / Q000502:physiology*
D004791:Enzyme Inhibitors; D007375:Interleukin-1; D010741:Phospholipases A; D054513:Group IV Phospholipases A2; D015232:Dinoprostone